ReviewNature reviews. Cardiology2026
Molecular imaging of immune and fibrosis targets to guide therapy for repair after myocardial infarction.
Review in Nature reviews. Cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Fibrosis-targeted, immunosuppressive dendritic cells mitigate cardiac adverse remodelling.Nature reviews. Cardiology · 2026Article
- A Flexible Wearable Electronics System for Electrocardiographic Assessment of Colchicine Therapy for Post-MI Remodeling.Sensors (Basel, Switzerland) · 2026Article
- Low-dose IL-2 therapy reduces arterial inflammation in acute coronary syndromes.Nature reviews. Cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart injury after acute myocardial infarction requires adequate repair to prevent left ventricular remodelling and the development of chronic heart failure. The early immune response to myocardial injury and its tight interconnection to fibroblast activation have a crucial role in determining the outcome after myocardial infarction. Emerging therapies aim to exploit these targets, harnessing the subacute window after cardiac injury to prevent subsequent contractile dysfunction. Given the complexity of the tissue response to myocardial injury and the molecular specificity of targeted therapies, only a subgroup of individuals might benefit from these therapies, which emphasizes the need for personalized therapies and the identification of suitable biomarkers to classify patients. Radiotracer-based, non-invasive molecular imaging is rapidly evolving alongside targeted drug development, providing novel tools for the investigation of immune and profibrotic mechanisms. These molecular imaging techniques hold unique potential to guide the development and selection of reparative therapies based on precise information about the most suitable candidates and the timing after acute myocardial infarction. In this Review, we outline a roadmap for the clinical implementation of radiotracer-based molecular imaging of immune and fibrotic pathways to guide targeted therapies for heart repair. The long-term goal is to establish clinical algorithms for immune-targeted and fibrosis-targeted imaging-guided therapy for cardiac repair.
Indexed as
Identifiers
41478884What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.